Good news! We’ve made it easier for Texas Children’s Health Plan members to log in to the MyChart website. Now, you can access all your MyChart health care features anytime, anywhere using our new sign-in widget. Click the link to log in now
¡Buenas noticias! Hemos hecho más fácil el inicio de sesión en MyChart para nuestros miembros de Texas Children’s Health Plan. Ahora puedes acceder a todas las funciones de cuidado médico de MyChart en cualquier momento y desde cualquier lugar mediante nuestro nuevo widget de inicio de sesión. Haz clic en el enlace para iniciar sesión.
Important UpdateActualización importante:
Good news! All CHIP, STAR, and STAR Kids Member Handbooks are now available online. Quick, easy access to your benefits and coverage information - any time!
¡Buenas noticias! Todos los manuales para miembros de CHIP, STAR y STAR Kids ya están disponibles en línea. Obtén acceso rápido y sencillo a la información sobre tus beneficios y cobertura, ¡en cualquier momento!
Prior Authorization Criteria Updated for Uplizna to Include Generalized Myasthenia Gravis
Date: August 31, 2026
Attention: All Providers
Effective date: November 1, 2026
Call to action: Texas Children's Health Plan (TCHP) would like to inform providers that effective for dates of service on or after November 1, 2026, Texas Medicaid will update prior authorization criteria for inebilizumab-cdon (Uplizna) (procedure code J1823) to include generalized myasthenia gravis (gMG).
Prior Authorization Requirements
The U.S. Food & Drug Administration (FDA) has approved gMG as an indication in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
The Texas Medicaid & Healthcare Partnership (TMHP) will consider prior authorization requests for gMG for a 12-month duration when the patient meets the following criteria:
The patient is 18 years of age or older.
The patient has a diagnosis of gMG, Myasthenia Gravis Foundation of America (MGFA) clinical classification of II, III, or IV (diagnosis codes G7000 and G7001).
The patient is anti-AChR or anti-MuSK antibody positive.
The patient’s Myasthenia Gravis-Activities of Daily Living (MG-ADL) score is between six and ten.
The patient has a Quantitative Myasthenia Gravis (QMG) score greater than 11.
The patient is on a stable dose of corticosteroid, a specific non-steroidal immunosuppressive therapy, or a combination of both.
The patient is not receiving inebilizumab-cdon (Uplizna) to treat myasthenia gravis concomitantly with the following therapies:
Anti-CD20 monoclonal antibody treatments
Complement inhibitors (such as ravulizumab-cwvz [Ultomiris] or zilucoplan [Zilbrysq])
A neonatal Fc receptor (FcRn) blocker (such as nipocalimab-aahu [Imaavy], rozanolixizumab-noli [Rystiggo], efgartigimod alfa-fcab [Vyvgart], or efgartigimod alfa and hyaluronidase-qvfc [Vygart Hytrulo])
Next step for providers: Providers should share this information with their staff.
